PB2366: TRIAL IN PROGRESS: PHASE 1 TRIAL EVALUATING THE SAFETY AND TOLERABILITY OF ODRONEXTAMAB IN COMBINATION WITH CEMIPLIMAB IN RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA

Títulos similares

• PB2366: TRIAL IN PROGRESS: PHASE 1 TRIAL EVALUATING THE SAFETY AND TOLERABILITY OF ODRONEXTAMAB IN COMBINATION WITH CEMIPLIMAB IN RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA
  por: Cecilia Carmen Carpio Segura, et al.
  Publicado: (2023-08-01)
• PB2335: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB PLUS CHOP (O-CHOP) VERSUS R-CHOP IN PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA (OLYMPIA-3)
  por: Benoit Tessoulin, et al.
  Publicado: (2023-08-01)
• PB2267: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB VERSUS INVESTIGATOR’S CHOICE IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (OLYMPIA-1)
  por: Stefano Luminari, et al.
  Publicado: (2023-08-01)
• PB2275: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB PLUS CHEMOTHERAPY VERSUS RITUXIMAB PLUS CHEMOTHERAPY IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (OLYMPIA-2)
  por: Silvana Novelli, et al.
  Publicado: (2023-08-01)
• PB2343: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB VERSUS STANDARD OF CARE THERAPY IN RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA (OLYMPIA-4)
  por: Eliza A. Hawkes, et al.
  Publicado: (2023-08-01)